Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children

Published:2015-09-21 Issue:1 Volume:51 Page:72-78
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Philippe M,Goutelle S,Guitton J,Fonrose X,Bergeron C,Girard P,Bertrand Y,Bleyzac N

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2015218.pdf

Reference51 articles.

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353.

2. Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114: 944–950.

3. Cohen A, Békássy AN, Gaiero A, Faraci M, Zecca S, Tichelli A et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41: S43–S48.

4. Faraci M, Barra S, Cohen A, Lanino E, Grisolia F, Miano M et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63: 1568–1575.

5. Faraci M, Békássy AN, De Fazio V, Tichelli A, Dini G, EBMT Paediatric and Late Effects Working Parties. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant 2008; 41: S49–S57.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions;Expert Opinion on Drug Metabolism & Toxicology;2023-02-01

2. Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children;Pharmaceutics;2022-10-01

3. External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients;Frontiers in Pharmacology;2022-07-07

4. The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study;Frontiers in Pharmacology;2022-06-16

5. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis;Transplantation and Cellular Therapy;2022-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3